Improving diagnosis and treatment of Myelodysplastic Syndromes in Spain
Official title: Unified platforM for a Better integRal Evaluation of MyeLodyspLastic Syndromes in SpAin-Strategy for Unraveling Personalized genoMic Medicine in Public heAlth System (UMBRELLA-SUMMA)
Run by Instituto de Investigación Biomédica de Salamanca · NCT06379945 · Data updated 2026-11-12
This study is trying to improve how doctors diagnose and treat Myelodysplastic Syndromes in Spain by using new techniques to find genetic changes in patients.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Instituto de Investigación Biomédica de Salamanca Academic / other |
| Locations | 4 sites (Badalona, Barcelona and 3 other locations) |
| Status | Recruiting |
| Started | January 1, 2024 |
| Main results expected | January 1, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | May 2, 2025 |
| Trial ID | NCT06379945 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults over 18 years old with a confirmed diagnosis of Myelodysplastic Syndromes.
✕Probably not a fit
Patients under 18 years old or those who do not provide informed consent will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The UMBRELLA-SUMMA project aims to enhance the clinical management of Myelodysplastic Syndromes (MDS) in Spain through advanced diagnostic and prognostic techniques. It utilizes Optical Genome Mapping (OGM) to identify chromosomal alterations in MDS patients, particularly in cases where traditional methods fail. Additionally, the project expands access to Next Generation Sequencing (NGS) for prognostic stratification and employs Artificial Intelligence to refine prognostic models. This initiative is supported by a collaboration of over 400 professionals across more than 100 centers in Spain.
Why it matters
Potential benefit: If successful, this project could lead to more accurate diagnoses and personalized treatment plans for MDS patients, improving their overall outcomes.
How similar studies have gone: Other studies utilizing advanced genomic technologies and AI in hematologic malignancies have shown promising results, indicating potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients over 18 years old * Patients with a confirmed diagnosis of MDS by cytogenetics and/or morphological analysis * Patients with complete clinical data * Patients who sign the informed consent Exclusion Criteria: * Patients under 18 years old * Patients who do not sign the informed consent
Where it's running
-
Fundación Instituto de Investigación Germans Trias i Puyol
Badalona, Barcelona, Spain Recruiting -
Hospital Universitario Vall d´Hebron
Barcelona, Spain Recruiting -
Clínica Universitaria de Navarra
Pamplona, Spain Recruiting -
Complejo Asistencial Universitario de Salamanca
Salamanca, Spain Recruiting
Study contacts
- Study coordinator: María Díez Campelo, PhD MD
- Email: mdiezcampelo@usal.es
- Phone: +34 923 29 11 00
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Age-stratified conditioning regimens to improve outcomes in haploidentical stem cell transplant for myelodysplastic syndrome
This study tests two conditioning regimens in adults with MDS undergoing haploidentical stem cell transplant to see how age affects outcomes over one year.
-
FXS0683 in relapsed or refractory blood cancers
This first‑in‑human study tests FXS0683 in adults with relapsed or refractory B‑cell lymphoma, AML, MDS, or ALL to see if it is safe, how the drug behaves in the body, and whether it shows any antitumor activity.
-
Brain network changes in adults with anemia measured by fNIRS
This project will use functional near-infrared spectroscopy (fNIRS) to see if brain network connections are altered in adults aged 18–65 who have anemia.
-
Cord blood transplant for children and young adults with blood cancers.
This study will test whether a cord blood transplant given as a first or second transplant can help children and young adults with leukemia, myelodysplasia, or lymphoma who lack a matched donor.
-
Reduced-intensity donor stem cell transplant with treosulfan/fludarabine and post-transplant cyclophosphamide for leukemia and MDS
This trial tests a lower-intensity donor stem cell transplant using treosulfan plus fludarabine with post-transplant cyclophosphamide to try to reduce toxicity and prevent graft-versus-host disease in people aged 2–75 with acute leukemias or myelodysplastic syndromes.
-
Electronic mindfulness-based music therapy for patients receiving stem cell transplantation
This trial tests an eHealth mindfulness-based music therapy to see if it improves quality of life and reduces symptoms for adults undergoing stem cell transplantation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.